US20020055177A1
(en)
*
|
1999-03-10 |
2002-05-09 |
Glaxo Wellcome Inc. |
Compound and its use
|
AU763244B2
(en)
*
|
2000-01-03 |
2003-07-17 |
Rpg Life Sciences Limited |
A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
|
CA2433181C
(en)
|
2000-12-29 |
2005-11-22 |
Pfizer Limited |
Amlodipine hemifumarate
|
AT5874U1
(de)
|
2000-12-29 |
2003-01-27 |
Bioorg Bv |
Pharmazeutische zubereitungen enthaltend amlodipinmaleat
|
US6653481B2
(en)
|
2000-12-29 |
2003-11-25 |
Synthon Bv |
Process for making amlodipine
|
GB2372036B
(en)
|
2000-12-29 |
2004-05-19 |
Bioorg Bv |
Aspartate derivative of amlodipine
|
BR0116554A
(pt)
|
2000-12-29 |
2004-02-03 |
Pfizer Ltd |
Composto, composição farmacêutica para o tratamento da angina ou hipertensão, processo, processo para o tratamento ou prevenção da angina ou hipertensão, composição do ingrediente farmaceuticamente ativo e composição farmacêutica para o tratamento ou prevenção da angina ou hipertensão
|
BR0116557A
(pt)
|
2000-12-29 |
2003-10-28 |
Pfizer Ltd |
Processo, processo para fabricação de um sal de maleato de amlodipina substancialmente livre de aspartato de amlodipina, processo para purificação, maleato de amlodipina, composição farmacêutica para tratar ou prevenir angina ou hipertenção, método para tratar hipertenção, angina ou ataque cardìaco, benzeno sulfonato de amlodipina, hidrocloreto de amlodipina e uso de maleato de amlodipina substancialmente livre de aspartato de amlodipina
|
MXPA03005882A
(es)
|
2000-12-29 |
2005-04-19 |
Pfizer Ltd |
Derivado amida de amlodipina.
|
CA2433284A1
(en)
*
|
2000-12-29 |
2002-07-11 |
Pfizer Limited |
Reference standards and processes for determining the purity or stability of amlodipine maleate
|
WO2002053539A1
(en)
|
2000-12-29 |
2002-07-11 |
Pfizer Limited |
Amlodipine hemimaleate
|
US7335380B2
(en)
|
2000-12-29 |
2008-02-26 |
Synthon Ip Inc. |
Amlodipine free base
|
DE10134980C2
(de)
|
2001-07-17 |
2003-05-28 |
Helm Ag |
Verfahren zur Herstellung von Lamotrigin
|
CA2366521C
(en)
|
2001-12-24 |
2007-03-06 |
Brantford Chemicals Inc. |
A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
|
WO2003080065A1
(en)
*
|
2002-03-20 |
2003-10-02 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of quetiapine hemifumarate
|
HU225667B1
(en)
*
|
2002-09-20 |
2007-05-29 |
Richter Gedeon Nyrt |
Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
|
ES2209639B1
(es)
|
2002-10-31 |
2005-08-01 |
Vita Cientifica, S.L. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
|
GB2395483A
(en)
*
|
2003-07-03 |
2004-05-26 |
Jubilant Organosys Ltd |
Crystalline lamotrigine and its monohydrate
|
CA2657076A1
(en)
|
2003-08-28 |
2005-03-17 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of rosuvastatin calcium
|
US7777034B2
(en)
*
|
2003-11-24 |
2010-08-17 |
Teva Pharmaceutical Industries Ltd. |
Crystalline ammonium salts of rosuvastatin
|
ES2364143T3
(es)
*
|
2003-12-02 |
2011-08-25 |
Teva Pharmaceutical Industries Ltd. |
Estandar de referencia para caracterización de rosuvastatina.
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
WO2005074935A1
(en)
*
|
2004-01-30 |
2005-08-18 |
Teva Pharmaceutical Industries Ltd. |
Montelukast free acid polymorphs
|
US20050187244A1
(en)
*
|
2004-01-30 |
2005-08-25 |
Entire Interest. |
Montelukast sodium polymorphs
|
MD2823G2
(ro)
*
|
2004-02-12 |
2006-05-31 |
Институт Химии Академии Наук Молдовы |
Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
|
CA2563776A1
(en)
*
|
2004-04-21 |
2005-11-10 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing montelukast sodium
|
WO2005105768A2
(en)
*
|
2004-04-26 |
2005-11-10 |
Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg |
Process for preparation of mycophenolic acid and ester derivatives thereof
|
US7358247B2
(en)
*
|
2004-04-27 |
2008-04-15 |
TEVA Gyógyszergyár Zártköruen Muködö Részvénytársaság |
Mycophenolate mofetil impurity
|
WO2006004977A2
(en)
*
|
2004-06-28 |
2006-01-12 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Process for the optical resolution and recycling of tomoxetine
|
US7439399B2
(en)
*
|
2004-06-28 |
2008-10-21 |
Teva Pharmaceutical Fine Chemicals |
Processes for the preparation of atomoxetine hydrochloride
|
CA2573857A1
(en)
*
|
2004-07-13 |
2006-02-16 |
Teva Pharmaceutical Industries Ltd. |
A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
|
US7439373B2
(en)
*
|
2004-07-20 |
2008-10-21 |
TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság |
Crystalline mycophenolate sodium
|
WO2006020348A2
(en)
*
|
2004-07-22 |
2006-02-23 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Polymorphs of atomoxetine hydrochloride
|
EP1692134A2
(en)
*
|
2004-09-04 |
2006-08-23 |
Teva Pharmaceutical Industries, Inc. |
A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
|
US20060081361A1
(en)
*
|
2004-09-13 |
2006-04-20 |
Gabbey Lawrence W |
Oil cooler with integral filter
|
CN101124230A
(zh)
*
|
2004-09-28 |
2008-02-13 |
特瓦制药工业有限公司 |
制备基本无杂质的阿托伐他汀钙形式的方法
|
JP2007514777A
(ja)
*
|
2004-10-19 |
2007-06-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
テガセロッドマレエートの精製
|
US7678551B2
(en)
*
|
2004-10-25 |
2010-03-16 |
Seradyn, Inc. |
Immunoassays for lamotrigine
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
ATE444950T1
(de)
*
|
2005-01-11 |
2009-10-15 |
Teva Pharm Fine Chemicals Srl |
Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
TWI345562B
(en)
|
2005-02-22 |
2011-07-21 |
Teva Pharma |
Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
|
EP1866295A2
(en)
*
|
2005-02-24 |
2007-12-19 |
Teva Pharmaceutical Industries Ltd |
Processes for the preparation of linezolid intermediate
|
WO2006099433A1
(en)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Pure duloxetine hydrochloride
|
WO2006108120A1
(en)
*
|
2005-04-05 |
2006-10-12 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
|
CN101160281A
(zh)
*
|
2005-04-06 |
2008-04-09 |
特瓦制药工业有限公司 |
结晶形态的普瑞巴林
|
CN101300224A
(zh)
*
|
2005-04-11 |
2008-11-05 |
特瓦制药工业有限公司 |
制备(s)-普瑞巴林的方法
|
US7488846B2
(en)
*
|
2005-04-11 |
2009-02-10 |
Teva Pharmaceuical Industries Ltd. |
Pregabalin free of lactam and a process for preparation thereof
|
JP2008502707A
(ja)
*
|
2005-04-14 |
2008-01-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
クエチアピンフマレートの調製方法
|
US20080280977A1
(en)
*
|
2005-04-26 |
2008-11-13 |
Sandor Molnar |
Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
|
MX2007000525A
(es)
*
|
2005-05-10 |
2007-03-28 |
Teva Pharma |
Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella.
|
EP1879852A1
(en)
*
|
2005-05-10 |
2008-01-23 |
Teva Pharmaceutical Industries Ltd |
Pregabalin free of lactam and a process for preparation thereof
|
EP1879854B1
(en)
*
|
2005-05-10 |
2011-09-07 |
Teva Pharmaceutical Industries Ltd |
Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
|
DE602006017995D1
(de)
*
|
2005-05-10 |
2010-12-16 |
Teva Pharma |
Verfahren zur herstellung von pregabalin und salzen daraus
|
MX2007000983A
(es)
|
2005-05-23 |
2007-04-16 |
Teva Pharma |
Procesos para preparar la forma cristalina i de clorhidrato de cinacalcet.
|
WO2007002720A2
(en)
*
|
2005-06-27 |
2007-01-04 |
Sicor, Inc. |
An impurity of anastrozole intermediate, and uses thereof
|
CN101208312A
(zh)
*
|
2005-06-27 |
2008-06-25 |
西科尔公司 |
用于合成阿那曲唑及纯化一种阿那曲唑中间体的方法
|
ES2358923T3
(es)
*
|
2005-07-05 |
2011-05-16 |
Teva Pharmaceutical Industries, Ltd. |
Purificación de montelukast.
|
MX2007004427A
(es)
*
|
2005-08-16 |
2007-06-14 |
Teva Pharma |
Intermedio de rosuvastatina cristalina.
|
WO2007035890A1
(en)
*
|
2005-09-19 |
2007-03-29 |
Teva Pharmaceutical Industries Ltd. |
An asymmetric synthesis of ( s ) - ( + ) -3- (aminomethyl) -5-methylhexanoic acid
|
US20070197529A1
(en)
*
|
2005-12-01 |
2007-08-23 |
Viviana Braude |
Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
|
US7759500B2
(en)
*
|
2005-12-05 |
2010-07-20 |
Teva Pharmaceutical Industries Ltd. |
2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
|
WO2007069264A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Alembic Limited |
Reference standards for determining the purity of telithromycin and processes therefor
|
CA2630478A1
(en)
*
|
2005-12-27 |
2007-07-05 |
Teva Pharmaceutical Industries, Ltd |
Processes for preparing darifenacin hydrobromide
|
MX2007014913A
(es)
*
|
2006-03-27 |
2008-10-24 |
Teva Pharma |
Proceso para perparar clorhidrato de memantina sustancialmente libre de impurezas.
|
US20080146675A1
(en)
*
|
2006-04-05 |
2008-06-19 |
Eugenio Castelli |
Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
|
GB0609835D0
(en)
*
|
2006-05-18 |
2006-06-28 |
Pliva Istrazivanje I Razvoj D |
Impurities of a pharmaceutical product
|
US7462738B2
(en)
*
|
2006-05-24 |
2008-12-09 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
|
WO2007143152A2
(en)
*
|
2006-05-31 |
2007-12-13 |
Teva Pharmaceutical Industries Ltd. |
Preparation of (s)-pregabalin-nitrile
|
EP2071032A3
(en)
*
|
2006-05-31 |
2009-07-08 |
Teva Pharmaceutical Industries Ltd |
The use of enzymatic resolution for the preparation of intermediates of pregabalin
|
DE602007004728D1
(de)
*
|
2006-06-29 |
2010-03-25 |
Ivax Pharmaceuticals Sro |
Regulation der säuremetabolitproduktion
|
US20120142919A1
(en)
*
|
2006-08-02 |
2012-06-07 |
Medichem, S.A. |
Method for synthesizing lamotrigine
|
CA2659290A1
(en)
*
|
2006-08-14 |
2008-02-21 |
Jean-Paul Roduit |
A process for the preparation of lamotrigine
|
EP2139845A1
(en)
*
|
2007-02-26 |
2010-01-06 |
Teva Pharmaceutical Industries Ltd. |
Intermediates and processes for the synthesis of ramelteon
|
MX2008014759A
(es)
*
|
2007-03-22 |
2009-03-09 |
Teva Pharma |
Sintesis del acido (s)-(+)-3-(aminometil)-5-metil hexanoico.
|
WO2008127663A1
(en)
*
|
2007-04-11 |
2008-10-23 |
Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság |
Method for reducing impurity level in mycophenolic acid fermentation
|
EP2098519A1
(en)
*
|
2007-05-31 |
2009-09-09 |
Teva Pharmaceutical Industries Ltd. |
Process for the synthesis of ramelteon and its intermediates
|
KR20090101462A
(ko)
*
|
2007-10-03 |
2009-09-28 |
테바 파마슈티컬 인더스트리즈 리미티드 |
프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
|
ES2565521T5
(es)
*
|
2007-10-23 |
2019-12-10 |
Teva Pharma |
Polimorfos de dasatinib y proceso para la preparación de los mismos
|
WO2009056993A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
A process for the synthesis of ramelteon and its intermediates
|
US8486927B2
(en)
*
|
2007-11-09 |
2013-07-16 |
Thar Pharmaceuticals |
Crystalline forms of lamotrigine
|
WO2009151494A1
(en)
*
|
2008-03-06 |
2009-12-17 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
|
KR20100107500A
(ko)
*
|
2008-06-23 |
2010-10-05 |
테바 파마슈티컬 인더스트리즈 리미티드 |
(s) 또는 (r)-이소-부틸-글루타릭 에스테르의 입체선택적 효소 합성방법
|
WO2010045565A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Teva Pharmaceutical Industries Ltd. |
Process for the synthesis of ramelteon and its intermediates
|
CA2795023A1
(en)
*
|
2010-03-29 |
2011-10-06 |
Pliva Hrvatska D.O.O. |
Crystal forms of o-desmethylvenlafaxine fumarate
|
WO2012034065A1
(en)
|
2010-09-09 |
2012-03-15 |
Teva Pharmaceutical Industries Ltd. |
Aliskiren intermediates and a process for analyzing the purity of aliskiren
|
CN102766104A
(zh)
*
|
2012-08-20 |
2012-11-07 |
三金集团湖南三金制药有限责任公司 |
一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
|
US10189859B2
(en)
|
2013-12-21 |
2019-01-29 |
Nektar Therapeutics |
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
|
CN110467560A
(zh)
|
2018-05-09 |
2019-11-19 |
深圳微芯生物科技股份有限公司 |
一种苯基氨基丙酸钠衍生物、其制备方法和应用
|
KR102270026B1
(ko)
*
|
2020-01-31 |
2021-06-28 |
현대약품 주식회사 |
(3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
|
CN113156009B
(zh)
*
|
2021-04-20 |
2023-12-22 |
三金集团湖南三金制药有限责任公司 |
高效液相色谱分析拉莫三嗪的方法
|